Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 417

1.

Novel biomarkers and genomic tests in prostate cancer: a critical analysis.

Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C.

Minerva Urol Nefrol. 2015 Jun 9. [Epub ahead of print]

PMID:
26054411
2.

The TMPRSS2-ERG gene fusion blocks XRCC4-mediated non-homologous end-joining repair and radiosensitizes prostate cancer cells to PARP inhibition.

Chatterjee P, Choudhary GS, Alswillah T, Xiong X, Heston WD, Magi-Galuzzi C, Zhang J, Klein EA, Almasan A.

Mol Cancer Ther. 2015 May 29. pii: molcanther.0865.2014. [Epub ahead of print]

PMID:
26026052
3.

High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.

Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, Davicioni E, Feng FY.

Prostate Cancer Prostatic Dis. 2015 May 19. doi: 10.1038/pcan.2015.22. [Epub ahead of print]

PMID:
25986914
4.

Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes.

Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY.

Eur Urol. 2015 May 8. pii: S0302-2838(15)00375-9. doi: 10.1016/j.eururo.2015.04.033. [Epub ahead of print]

PMID:
25964175
5.

Long-Term Efficacy and Toxicity of Low-Dose-Rate (125)I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.

Kittel JA, Reddy CA, Smith KL, Stephans KL, Tendulkar RD, Ulchaker J, Angermeier K, Campbell S, Stephenson A, Klein EA, Wilkinson DA, Ciezki JP.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):884-93. doi: 10.1016/j.ijrobp.2015.02.047. Epub 2015 May 8.

PMID:
25962627
6.

Two susceptibility loci identified for prostate cancer aggressiveness.

Berndt SI, Wang Z, Yeager M, Alavanja MC, Albanes D, Amundadottir L, Andriole G, Beane Freeman L, Campa D, Cancel-Tassin G, Canzian F, Cornu JN, Cussenot O, Diver WR, Gapstur SM, Grönberg H, Haiman CA, Henderson B, Hutchinson A, Hunter DJ, Key TJ, Kolb S, Koutros S, Kraft P, Le Marchand L, Lindström S, Machiela MJ, Ostrander EA, Riboli E, Schumacher F, Siddiq A, Stanford JL, Stevens VL, Travis RC, Tsilidis KK, Virtamo J, Weinstein S, Wilkund F, Xu J, Lilly Zheng S, Yu K, Wheeler W, Zhang H; African Ancestry Prostate Cancer GWAS Consortium, Sampson J, Black A, Jacobs K, Hoover RN, Tucker M, Chanock SJ.

Nat Commun. 2015 May 5;6:6889. doi: 10.1038/ncomms7889.

PMID:
25939597
7.

Prostate cancer: MR-TRUS fusion biopsy--defining a new standard.

Klein EA.

Nat Rev Clin Oncol. 2015 May;12(5):253-4. doi: 10.1038/nrclinonc.2015.70. Epub 2015 Apr 14. No abstract available.

PMID:
25869459
8.

For Single Dosing, Levofloxacin Is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy.

Unnikrishnan R, El-Shafei A, Klein EA, Jones JS, Kartha G, Goldman HB.

Urology. 2015 Jun;85(6):1241-6. doi: 10.1016/j.urology.2014.12.062. Epub 2015 Apr 8.

PMID:
25863835
9.

Influence of zonal dosimetry on prostate brachytherapy outcomes.

Hong CW, Reddy CA, Wilkinson DA, Klein EA, Ciezki JP.

J Contemp Brachytherapy. 2015 Feb;7(1):17-22. doi: 10.5114/jcb.2015.48875. Epub 2015 Feb 4.

10.

A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.

Rini BI, Plimack ER, Takagi T, Elson P, Wood LS, Dreicer R, Gilligan T, Garcia J, Zhang Z, Kaouk J, Krishnamurthi V, Stephenson AJ, Fergany A, Klein EA, Uzzo RG, Chen DY, Campbell SC.

J Urol. 2015 Mar 23. pii: S0022-5347(15)03398-4. doi: 10.1016/j.juro.2015.03.096. [Epub ahead of print]

PMID:
25813447
11.

Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group.

Nieboer D, Vergouwe Y, Roobol MJ, Ankerst DP, Kattan MW, Vickers AJ, Steyerberg EW; Prostate Biopsy Collaborative Group.

J Clin Epidemiol. 2015 Apr;68(4):426-34. doi: 10.1016/j.jclinepi.2014.11.022. Epub 2014 Nov 29.

PMID:
25777297
12.

Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.

Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F.

Clin Cancer Res. 2015 Jun 1;21(11):2591-600. doi: 10.1158/1078-0432.CCR-14-2603. Epub 2015 Mar 2.

PMID:
25733599
13.

Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.

Zhao B, Yerram NK, Gao T, Dreicer R, Klein EA.

Urol Oncol. 2015 Apr;33(4):164.e19-23. doi: 10.1016/j.urolonc.2015.01.001. Epub 2015 Feb 7.

PMID:
25665510
14.

CD117⁺ cells in the circulation are predictive of advanced prostate cancer.

Kerr BA, Miocinovic R, Smith AK, West XZ, Watts KE, Alzayed AW, Klink JC, Mir MC, Sturey T, Hansel DE, Heston WD, Stephenson AJ, Klein EA, Byzova TV.

Oncotarget. 2015 Jan 30;6(3):1889-97.

15.

Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database.

Shukla ME, Yu C, Reddy CA, Stephans KL, Klein EA, Abdel-Wahab M, Ciezki J, Tendulkar RD.

Clin Genitourin Cancer. 2015 Feb;13(1):17-21. doi: 10.1016/j.clgc.2014.07.003. Epub 2014 Jul 14.

PMID:
25571871
16.

Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form.

Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT; PROSTQA Consortium.

Urology. 2015 Jan;85(1):101-5. doi: 10.1016/j.urology.2014.08.044.

PMID:
25530370
17.

The feline oral microbiome: a provisional 16S rRNA gene based taxonomy with full-length reference sequences.

Dewhirst FE, Klein EA, Bennett ML, Croft JM, Harris SJ, Marshall-Jones ZV.

Vet Microbiol. 2015 Feb 25;175(2-4):294-303. doi: 10.1016/j.vetmic.2014.11.019. Epub 2014 Dec 2.

18.

A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E.

Eur Urol. 2015 Apr;67(4):778-86. doi: 10.1016/j.eururo.2014.10.036. Epub 2014 Nov 12.

PMID:
25466945
19.

RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.

Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY.

Lancet Oncol. 2014 Dec;15(13):1469-80. doi: 10.1016/S1470-2045(14)71113-1. Epub 2014 Nov 17.

PMID:
25456366
20.

Surgical outcomes after cytoreductive nephrectomy with inferior vena cava thrombectomy.

Westesson KE, Klink JC, Rabets JC, Fergany AF, Klein EA, Stephenson AJ, Rini BI, Navia J, Krishnamurthi V.

Urology. 2014 Dec;84(6):1414-9. doi: 10.1016/j.urology.2014.05.078. Epub 2014 Oct 16.

PMID:
25440988
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk